Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study
On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral.
Arcellx Inc. (ACLX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | SR One Capital Simeon George | 2,346,630 | $153,000,276 | 21.66% | |
| 2. | Hudson Bay Capital Management Sander Gerber | 400,942 | $26,141,418 | 0.09% | |
| 3. | Fisher Asset Management Ken Fisher | 322,855 | $21,050,146 | 0.01% | |
| 4. | Rhenman & Partners Asset Management Henrik Rhenman | 133,500 | $8,704,200 | +105% | 0.81% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 49,875 | $3,251,850 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 312,500 | $5,000,000.00 | 6,745,262 | 2022-06-21 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing | |
| $15.00 | 66,667 | $1,000,005.00 | 3,466,811 | 2022-02-08 | Filing | |
| $15.00 | 1,583,333 | $23,749,995.00 | 6,432,762 | 2022-02-08 | Filing | |
| $15.00 | 1,600,000 | $24,000,000.00 | 2,033,196 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.00 | 6,000 | $450,000.00 | 21,659 | 2026-01-20 | Filing | |
| $68.51 | 5,882 | $402,997.00 | 23,749 | 2026-01-14 | Filing | |
| $65.51 | 7,437 | $487,212.74 | 29,631 | 2026-01-13 | Filing | |
| $64.15 | 6,131 | $393,285.87 | 37,068 | 2026-01-12 | Filing | |
| $90.00 | 340 | $30,600.00 | 284 | 2025-11-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,720,803 | $438,196,356 | 22.64% | |
| 2. | 4,081,519 | $266,115,040 | 0% | |
| 3. | 3,548,787 | $231,380,928 | 0% | |
| 4. | 1,998,503 | $130,302,396 | 0% | |
| 5. | 1,454,477 | $94,831,912 | 0.01% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect
Arcellx Inc. (NASDAQ:ACLX) is one of the best high short interest stocks with biggest upside potential.
11 Best High Short Interest Stocks With Biggest Upside Potential
On January 27, Sherry Paul, a senior portfolio manager at Morgan Stanley, appeared on CNBC's 'Closing Bell' to discuss whether more volatility is ahead, following a volatile week in the market.
Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment
Arcellx Inc. (NASDAQ:ACLX) is one of the best biotech stocks to buy according to Wall Street analysts.
15 Best Biotech Stocks to Buy According to Wall Street Analysts
The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain for the S&P 500 over the same period.
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting
On November 25, 2025, Arcellx, Inc. (NASDAQ:ACLX) saw Morgan Stanley’s Judah Frommer reiterate a “Buy” rating.
12 Oversold Global Stocks to Invest In
Appearing in an interview with CNBC on November 21, 2025, David Katz of Matrix Asset Advisors called widespread weakness a potential entry point, saying that the current correction is “much closer to...
Hedge Fund Resource Center Billionaire Hedge Funds
